Quincy Bioscience

Prevagen

TINA.org investigated the marketing of Prevagen, a supplement aimed at people suffering from memory loss, and found that Quincy Bioscience — the marketer and manufacturer of Prevagen — deceptively claimed the product could improve memory without having competent or reliable scientific evidence to support such a claim.


Highlights

  • Notified company of findings
  • Filed complaint with FTC
  • FTC and NY attorney general filed enforcement action
  • Notified major TV networks airing Prevagen ads of deception
  • Filed brief in Second Circuit supporting FTC and NY attorney general's suit
  • Objected to class-action settlement
Prevagen ad

Timeline

September 17, 2021: The FTC’s claims for monetary relief in its lawsuit against Quincy Bioscience are dismissed When a complaint is dismissed without prejudice, an amended version of the complaint can be refiled. due to the Supreme Court’s decision in the AMG Capital Mgmt., LLC v. FTC case.

November 18, 2020: After a Final Fairness Hearing, the Collins Court grants final approval of the settlement agreement.

November 16, 2020: The FTC sends a letter to the Collins Court to address certain arguments made in the parties’ responses to TINA.org’s amicus brief. Among other things, the FTC stated that (1) the absence of a formal brief from the FTC (or NYAG) opposing the proposed settlement should not be interpreted as acquiescence to, or approval of, the settlement terms; (2) it continues to believe that Quincy Bioscience has not proffered competent and reliable scientific evidence to substantiate memory or other cognitive claims for Prevagen; and (3) the FTC and NYAG intend to proceed with their law enforcement action and will seek both broad injunctive relief and related equitable relief including restitution in the form of consumer refunds.

November 9, 2020: Plaintiffs and defendant in the Collins case respond to TINA.org’s brief. Both parties argue, among other things, that the FTC’s lack of objection in this case amounts to its tacit approval of the proposed settlement terms.

October 27, 2020: TINA.org files a brief as amicus curiae opposing the proposed settlement in the Collins case, as well as a Motion for Leave to file the brief.

June 24, 2020: The parties in the Collins case reach a settlement agreement.

July 18, 2019: TINA.org sends a follow-up letter to the FTC regarding ineffective changes to Quincy Bioscience’s deceptive marketing for Prevagen.

July 11, 2019: A class-action lawsuit is filed against Quincy Bioscience for falsely advertising that Prevagen improves memory within 90 days and supports “Healthy Brain Function,” “Sharper Mind,” and “Clearer Thinking.” The case is called Collins v. Quincy Bioscience, LLC.

May 16, 2019: TINA.org provides comment to the FDA regarding supplement marketers’ use of unsubstantiated disease-treatment claims (providing Prevagen’s marketing as an example), and urging the agency to do more to protect susceptible populations, including the elderly.

February 21, 2019: The Second Circuit Court of Appeals issued a Summary Order vacating the District Court’s judgment and remanding the case for further proceedings.

January 4, 2019: The Second Circuit Court of Appeals grants TINA.org’s Motion for Leave to file an amicus brief.

March 6, 2018: TINA.org, AARP, AARP Foundation, National Consumers League, and a group of advertising law academics file a Motion for Leave to file an amici curiae brief in support of reversing the District Court’s decision.

March 5, 2018: The FTC files its appellate brief arguing that its case was improperly dismissed by the District Court.

February 28, 2018: The New York AG files its appellate brief arguing that its case was improperly dismissed by the District Court.

November 15, 2017: The FTC and New York AG file Notices of Appeal indicating that they will be appealing the dismissal decision to the Second Circuit Court of Appeals.

October 2017: The BBB changes its rating of Quincy Bioscience back to an A+.

September 28, 2017: The FTC and New York Attorney General’s lawsuit filed against Quincy Bioscience was dismissed because the Court determined that they failed to show that the company lacks proper substantiation for its claims about Prevagen’s ability to improve memory.

January 10, 2017: The BBB changes its A+ rating of Quincy Bioscience to “No Rating.”

January 9, 2017: The FTC, together with the New York Attorney General, file a lawsuit against Quincy Bioscience for its deceptive advertising of Prevagen as able to improve memory.

After the filing of the lawsuit, TINA.org sends letters to the same five major TV networks it had notified in January 2016 (ABC, NBC, FOX, The Weather Channel, and Turner Broadcasting System) to notify them of the federal lawsuit filed against Quincy Bioscience and urging them to cease airing ads for Prevagen. TINA.org also sends a letter to the BBB notifying it of the lawsuit and urging it once again to re-evaluate its A+ rating of the company.

January 19, 2016: TINA.org sends letters to five major TV networks (ABC, NBC, FOX, The Weather Channel, and Turner Broadcasting System) that air Prevagen commercials putting them on notice that the commercials are deceptive and in violation of the networks’ own stated policies to only air truthful marketing.

TINA.org also sends a letter to the BBB calling on the organization to re-evaluate its A+ rating of Quincy Bioscience.

September 17, 2015: After getting no response from Quincy Bioscience, TINA.org sends a complaint letter to the FTC urging the agency to take action to halt the company’s deceptive marketing of Prevagen.

September 8, 2015: TINA.org sends a warning letter to Quincy Bioscience regarding its deceptive marketing campaign for Prevagen, and asking that the company correct the issues within one week.

October 16, 2012: The FDA sends a warning letter to Quincy Bioscience for, among other things, marketing Prevagen as a drug by claiming it can cure, mitigate, treat, or prevent disease, without FDA approval. At the time of the FDA’s warning letter, Quincy Bioscience specifically referred to Alzheimer’s Disease in some of its marketing materials.


Featured


The Latest

Filters

Comment at FDA Public Meeting on Dietary Supplements

Blog

Comment at FDA Public Meeting on Dietary Supplements

Comment made by TINA.org executive director, Bonnie Patten at the FDA’s public meeting on Responsible Innovation in Dietary Supplements held on May 16, 2019. Thank you for the opportunity to…


Show More


Class-Action Tracker

Prevagen Dietary Supplements

Class Action

Prevagen Dietary Supplements

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Quincy Bioscience’s Prevagen

Class Action

Quincy Bioscience’s Prevagen

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Prevagen Supplement

Class Action

Prevagen Supplement

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Prevagen Products

Class Action

Prevagen Products

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Quincy Bioscience’s Prevagen Supplement

Class Action

Quincy Bioscience’s Prevagen Supplement

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Prevagen Dietary Supplement

Class Action

Prevagen Dietary Supplement

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Prevagen Supplements

Class Action

Prevagen Supplements

A false advertising class-action lawsuit against Quincy Bioscience was dismissed in June 2016. The complaint, which was originally filed in state court in March 2015 and transferred to federal court…